News — Boulder Ventures Ltd.

Zenoss Cloud Posts 229% Year Over Year Growth

AUSTIN, Texas - January 22, 2021 - Zenoss Inc., the leader in AI-driven full-stack monitoring, today announced its company highlights for 2020. Among many noteworthy accomplishments, Zenoss saw record milestones in its Zenoss Cloud offering, the industry’s first full-stack monitoring plus AIOps platform.

Zenoss Cloud revenue grew by 229% compared to 2019. The AI-powered Zenoss Cloud platform was launched in mid-2018 and has been the company's flagship product, providing immediate root-cause analysis and preventing IT disruptions in any environment — from simple infrastructures to the most complex, dynamic multicloud IT deployments.

Matt PaulJanuary 22, 2021zenoss

Invitae Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions.

Matt PaulJanuary 22, 2021archerdx

Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)

SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of MRD as a biomarker in AML.

Matt PaulJanuary 14, 2021archerdx

Happy New Year from our Swiss Partners

Matt PaulJanuary 1, 2021

Deal of the Year CBSA Awards Celebration 2020

Jason Myers and his team were honored at the CBSA awards banquet last week with the Deal of the Year Award, a well-deserved honor. See video linked in the title of this article and embedded within.

Matt PaulDecember 14, 2020archerdx

Would you buy a gift you couldn't see to help find a cure for blindness?

Dec. 14, 2020 - 6:55 - Two Blind Brothers founders Bradford and Bryan Manning explain the idea behind their ‘Shop Blind’ challenge, which gives 100 percent of profits to the Foundation Fighting Blindness.

Matt PaulDecember 14, 2020

Backcountry Skiing: A Beginner’s Guide to the Sport of Covid Winter

You needn’t be a daredevil to go backcountry skiing—just willing to clomp up a hill. Around the U.S., several new spots are easing newcomers into a sport where utter seclusion is the whole point.

Matt PaulNovember 30, 2020

ULI Fall Event Innovation Fireside Chat

Black Bear Energy's Victoria Stulgis on Energy Storage deployment for LBA Realty's sustainability program as part of ULI's Fall Event Innovation Fireside Chat. Click the title to link to the video.

Matt PaulNovember 13, 2020black bear energy

LightDeck Diagnostics has $11 million for its new, high-speed way to test for COVID-19, sepsis and heart attack

LightDeck Diagnostics, a company formed earlier this year from the merger of startups mBio and Brava Diagnostics, has raised $11 million in funding for a new high-speed COVID-19 test, according to a statement.

Matt PaulOctober 29, 2020lightdeck